In GM-CSF/PGE2-conditioned naïve mouse bone-marrow cultures, licofelone reduced IMC frequencies at 2.5 and 5 µM and macrophage frequencies at 2.5–10 µM after 5 days. The IMC response at 10 µM was not significant, and CD11c+ cell frequencies were unchanged. These are live-cell population frequencies, not absolute cell counts. [2]
Cellular versus cell-free 5-LO product inhibition
Biochemical assay · Human PMNL, PMNL homogenates, and partially purified recombinant human 5-LO [1]
Licofelone at 10 µM inhibited 5-LO product formation in intact PMNL but did not significantly inhibit the cell-free preparations; the direct inhibitor BWA4C remained active. Adding DTT did not significantly restore inhibition in PMNL homogenates.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 µM in Figure 3a; concentration series up to 10 µM in Figure 3b
- Exposure duration
- Intact PMNL: 15-min pretreatment; cell-free Figure 3a: 5-min pretreatment; product formation measured after 10 min in shared methods
- Method
- In vitro addition; arachidonic acid 40 µM for Figure 3a; intact cells activated by A23187, cell-free preparations by calcium
- Vehicle
- DMSO
- Co-treatment
- No therapeutic combination; MK-886 and BWA4C are parallel comparator treatments
- Reported limits
- Figure 3a caption specifies 1 mM Ca2+ whereas general cell-free methods specify 2 mM CaCl2. Exact calcium concentration is unresolved; no calcium-dependent comparison or cell-free IC50 is claimed.
Methods and source locations
Compound reported in the paper: Licofelone; Compound label in the paper: ML3000
Evidence applies to the reported licofelone material and experimental context; no validation of the current A11697 lot or equivalence of formulations.
Figure 3a–b; shared “Determination of 5-LO product formation” methods; Statistics; Reagents
5-LO product formation: intact cells versus homogenates and partially purified enzyme: HPLC of summed 5-LO products; DMSO vehicle; MK-886 1 µM and BWA4C 1 µM comparators. Mean + s.e., n = 4; ANOVA/Tukey-HSD. — Figure 3a and Results, “Licofelone is a weak inhibitor of 5-LO activity in cell-free assays”
Effect of reducing conditions on licofelone inhibition in PMNL homogenates: Figure 3b: with/without 1 mM DTT across 2, 10 or 40 µM arachidonic acid; mean + s.e., n = 4; ANOVA/Tukey-HSD. — Figure 3b and corresponding Results
Stimulus-dependent inhibition of the cellular 5-LO pathway
Cell-based study · Freshly isolated human polymorphonuclear leukocytes (PMNL) [1]
Licofelone suppressed ionophore-induced 5-LO product formation more potently than product formation induced by hyperosmotic or genotoxic stress. Diamide also reduced efficacy in ionophore-stimulated cells.
Literature-Reported Treatment Conditions
- Treatment concentration
- Licofelone concentration series through 30 µM
- Exposure duration
- 15-min total pretreatment; stress agents added for final 3 min; 10-min product formation period
- Method
- Intact-cell assay at 37°C; arachidonic acid 40 µM. Ionophore stimulation compared with NaCl 300 mM or sodium arsenite 10 µM; diamide 500 µM is an additional oxidant condition
- Vehicle
- DMSO
- Co-treatment
- No therapeutic combination; MK-886 tested in parallel
- Reported limits
- Donor number is not specified for this figure; reported n = 4–5 is retained without reinterpreting it.
Methods and source locations
Compound reported in the paper: Licofelone; Compound label in the paper: ML3000
Evidence applies to the reported licofelone material and experimental context; no validation of the current A11697 lot or equivalence of formulations.
Figure 4; corresponding Results; intact-cell HPLC methods; Statistics; Reagents
5-LO product formation after ionophore plus arachidonic acid: HPLC; A23187 2.5 µM plus arachidonic acid 40 µM; DMSO vehicle and MK-886 comparator. Figure values mean + s.e., n = 4–5. — Figure 4 and Results, “The potency of licofelone depends on the stimulus to activate 5-LO”
5-LO product formation after hyperosmotic or genotoxic stress: HPLC; NaCl or sodium arsenite with arachidonic acid. Results report this bound for cell-stress conditions; it is not an exact curve estimate. — Figure 4 and corresponding Results
Licofelone alters myeloid-cell frequencies in bone-marrow cultures
Cell-based study · Bone-marrow cells from naïve C57BL/6 mice, cultured under GM-CSF/PGE2 differentiation conditions [2]
Licofelone reduced the live-cell frequency of Gr-1+ CD11b+ IMCs at 2.5 and 5 µM, but the 10 µM IMC response was not significant. F4/80+ CD11b+ Gr-1− macrophage frequencies were reduced at all three concentrations. CD11c+ cell frequencies were unchanged.
Literature-Reported Treatment Conditions
- Treatment concentration
- 2.5, 5 and 10 µM
- Exposure duration
- 5 days; licofelone, medium and cytokines refreshed every other day
- Method
- Addition to naïve bone-marrow cultures containing GM-CSF 20 ng/mL and PGE2 9.1 µg/mL
- Co-treatment
- GM-CSF and PGE2 are differentiation stimuli, not an antitumor combination treatment
- Reported limits
- Licofelone solvent/vehicle is not specified in the retrieved materials or IMC-generation methods. Figure 5 uses the 0 µM licofelone culture control. Absolute cell counts and a monotonic dose response are not established.
Methods and source locations
Compound reported in the paper: Licofelone
Evidence applies to the reported licofelone material and experimental context; no validation of the current A11697 lot or equivalence of formulations.
Figure 5A–C; Materials; “Generation and Phenotyping of IMCs”; Statistical Analysis; corresponding Results
Frequency of IMCs, macrophages and CD11c+ cells among live cells: Propidium-iodide-low live-cell gate; mean + SD, three independent experiments, n = 2/experiment; one-way ANOVA with Tukey comparison. Exact percentages are not inferred from bars. — Figure 5A–C and Results, “Licofelone Suppresses the Generation of Gr-1+ CD11b+ IMCs and Gr-1− F4/80+ Macrophages In Vitro”